Sonoma Pharmaceuticals Inc. [NASDAQ: SNOA] traded at a high on 01/25/23, posting a 40.83 gain after which it closed the day’ session at $1.69. The company report on January 25, 2023 that Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that Microcyn® Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).
The DAPA enables our partner, EMC Pharma, to enter into distribution agreements for Microcyn® Rx products with federal customers. The U.S. government is the world’s largest purchaser of good and services. Approximately half of EMC Pharma’s customers are U.S. government entities, including VA hospitals, the Department of Defense, the Federal Bureau of Prisons, as well as state and local prison systems. EMC Pharma is a 100% minority-owned and a certified Minority Business Enterprise (MBE).
The results of the trading session contributed to over 99148809 shares changing hands. Over the past one week, the price volatility of Sonoma Pharmaceuticals Inc. stands at 19.41% while the volatility over the past one month is 11.07%.
The market cap for SNOA stock reached $5.09 million, with 3.10 million shares outstanding and 3.09 million shares in the current float. Compared to the average trading volume of 762.87K shares, SNOA reached a trading volume of 99148809 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sonoma Pharmaceuticals Inc. [SNOA]?
The Average True Range (ATR) for Sonoma Pharmaceuticals Inc. is set at 0.20, with the Price to Sales ratio for SNOA stock in the period of the last 12 months amounting to 0.41. The Price to Book ratio for the last quarter was 0.75, with the Price to Cash per share for the same quarter was set at 1.13.
How has SNOA stock performed recently?
Sonoma Pharmaceuticals Inc. [SNOA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 34.14. With this latest performance, SNOA shares gained by 42.02% in over the last four-week period, additionally sinking by -48.48% over the last 6 months – not to mention a drop of -55.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNOA stock in for the last two-week period is set at 66.52, with the RSI for the last a single of trading hit 75.56, and the three-weeks RSI is set at 59.45 for Sonoma Pharmaceuticals Inc. [SNOA]. The present Moving Average for the last 50 days of trading for this stock 1.4595, while it was recorded at 1.3071 for the last single week of trading, and 2.5029 for the last 200 days.
Sonoma Pharmaceuticals Inc. [SNOA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sonoma Pharmaceuticals Inc. [SNOA] shares currently have an operating margin of -46.62 and a Gross Margin at +31.62. Sonoma Pharmaceuticals Inc.’s Net Margin is presently recorded at -40.28.
Return on Equity for this stock declined to -72.35, with Return on Assets sitting at -29.77.
Sonoma Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 3.50.
Insider trade positions for Sonoma Pharmaceuticals Inc. [SNOA]
There are presently around $0 million, or 5.80% of SNOA stock, in the hands of institutional investors. The top three institutional holders of SNOA stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 75,367, which is approximately -0.528% of the company’s market cap and around 0.39% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 36,878 shares of the stock with an approximate value of $62000.0 in SNOA stocks shares; and VANGUARD GROUP INC, currently with $57000.0 in SNOA stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Sonoma Pharmaceuticals Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 2 institutional holders increased their position in Sonoma Pharmaceuticals Inc. [NASDAQ:SNOA] by around 9,225 shares. Additionally, 6 investors decreased positions by around 15,305 shares, while 10 investors held positions by with 154,383 shares. The mentioned changes placed institutional holdings at 178,913 shares, according to the latest SEC report filing. SNOA stock had 0 new institutional investments in for a total of 0 shares, while 2 institutional investors sold positions of 213 shares during the same period.